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Abstract
Background: The 5-year survival rate of cancer patients is the most commonly used statistic to reflect improvements in the
war against cancer. This idea, however, was refuted based on an analysis showing that changes in 5-year survival over time
bear no relationship with changes in cancer mortality.
Methods: Here we show that progress in the fight against cancer can be evaluated by analyzing the association between 5-
year survival rates and mortality rates normalized by the incidence (mortality over incidence, MOI). Changes in mortality
rates are caused by improved clinical management as well as changing incidence rates, and since the latter can mask the
effects of the former, it can also mask the correlation between survival and mortality rates. However, MOI is a more robust
quantity and reflects improvements in cancer outcomes by overcoming the masking effect of changing incidence rates.
Using population-based statistics for the US and the European Nordic countries, we determined the association of changes
in 5-year survival rates and MOI.
Results: We observed a strong correlation between changes in 5-year survival rates of cancer patients and changes in the
MOI for all the countries tested. This finding demonstrates that there is no reason to assume that the improvements in 5-
year survival rates are artificial. We obtained consistent results when examining the subset of cancer types whose incidence
did not increase, suggesting that over-diagnosis does not obscure the results.
Conclusions: We have demonstrated, via the negative correlation between changes in 5-year survival rates and changes in
MOI, that increases in 5-year survival rates reflect real improvements over time made in the clinical management of cancer.
Furthermore, we found that increases in 5-year survival rates are not predominantly artificial byproducts of lead-time bias,
as implied in the literature. The survival measure alone can therefore be used for a rough approximation of the amount of
progress in the clinical management of cancer, but should ideally be used with other measures.
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Introduction
Improvements in the 5-year survival rates of cancer patients
have long been cited as proof of the increasing effectiveness of anti-
cancer treatment modalities both in scientific articles [1–4] and in
media and policy documents [5]. The use of 5-year survival rates
to reach this conclusion, however, was criticized in 1990 by Sondik
[6], who argued that improvements in diagnostic abilities can
contribute to increases in 5-year survival rates of cancer even in
the absence of any progress towards more effective clinical
interventions. Ten years ago, Welch, Schwartz and Woloshin [7]
carefully investigated this criticism. The authors posited that
improvements in cancer treatments should simultaneously increase
survival rates and reduce mortality rates, thus leading to a
correlation between the two, while improvements in survival rates
due to artificial causes (e.g. due to earlier diagnoses) would not be
related to decreased mortality. Indeed, they found no correlation
between improving survival rates and decreasing mortality rates,
which would seem to suggest that there have been no improve-
ments in cancer management. On the other hand, if incidence
rates were rising solely due to an increasing occurrence of cancer,
then no correlation with survival rates should be observed in
equilibrium. However, if the incidence was rising due to earlier
diagnoses, then a correlation with rising survival rates should be
detected; the latter was the case and a relationship was identified.
These results were interpreted as follows: ‘‘It has been reported
that improvements in treatment results for patients with malignant
disease represent spurious effects of diagnosis at an early stage’’
[8]. The insight that 5-year survival rates are a misleading measure
of real improvement has since become canonical and is now
included in standard textbooks on cancer biology [9]. Further-
more, these results also strongly call into question the efficiency of
clinical interventions for cancer patients, since a lack of correlation
between mortality rates and 5-year survival would seem to indicate
that clinical management of cancer does not have any positive
effects on patient survival.
PLOS ONE | www.plosone.org 1 July 2014 | Volume 9 | Issue 7 | e83100We hypothesized that changes in the mortality rate itself does
not fully capture improvements in cancer treatments and for this
reason may not correlate with increasing survival rates. Impor-
tantly, even if cancer treatments were effective for an increasing
number of patients, the mortality rate could still rise if the
incidence of the given cancer type itself was increasing.
To illustrate this point, consider for example non-Hodgkin
lymphoma. In the US, this disease had an age-adjusted incidence
rate of 11 and a mortality rate of 5.6 per 100,000 people per year
in 1975, and an incidence of 20 and a mortality rate of 7.9 per
100,000 per year in 2000 [10]. Although it seems that the outlook
for patients diagnosed with this particular type of cancer
deteriorated between 1975 and 2000, since the mortality rate
rose by 2.3, clinical management of this cancer type actually
improved dramatically, as the expected mortality rate in 2000
would have been 10.2. The expected mortality rate is determined
by the fact that the incidence almost doubled and therefore,
because the mortality rate is not reported as normalized by
incidence, it should have almost doubled as well. The fact that the
actual mortality rate only rose to 7.9 instead of the expected 10.2
signifies an improvement in the clinical management of the
disease.
Based on these considerations, a more indicative measure of an
improvement in cancer management should then be the change in
mortality rate normalized by the change in the incidence rate
(mortality over incidence, MOI). In the above example, rates of
5.6/11 in 1975 compared to 7.9/20 in 2000 reflect a 25%
improvement in the overall clinical management of the disease. At
the same time, the 5-year survival rate changed from 47% in 1975
to 70% in 2000. In this situation, the 5-year survival rate increased
but does not correlate with the change in mortality; it does,
however, correlate with the change in MOI. Despite the
similarities between the fatality rate (the proportion of deaths
within a designated population of cases) and the mortality over
incidence, these measures are not identical; the fatality rate is
obtained from a given case population, while mortality over
incidence does not necessarily use the same population for the
mortality and incidence. Nevertheless, due to the similarities
between these two concepts, MOI can serve as an approximation
for the fatality rate.
To investigate if the improvement in survival rates is related to
improvements in the clinical management of cancer, we thus need
to compare the change in survival to the change in MOI and not
to the change in mortality rate alone. In cases in which the
incidence remains unchanged, which is very uncommon, this
analysis reduces to the currently used approach of correlating
survival to mortality. Note that ‘‘improvements in clinical
management’’ refers to any changes in the way cancer patients
are dealt with clinically, including the administration of new drugs,
the use of a more effective dosing strategy of existing drugs, or
simply a cost reduction making previously available treatments
more affordable and thus more widely used.
Methods
Data
The age-adjusted incidence rates, mortality rates and 5-year
survival rates for US patients were obtained from the SEER
database using SEERStat (www.seer.cancer.gov/seerstat).
Throughout the paper, ‘‘survival’’ refers to relative but not overall
survival. We obtained data of all cancer types in the SEER
database and subdivided them into types according to available
definitions. For example, the classification ‘‘leukemia’’ was
subdivided into acute lymphocytic leukemia, chronic lymphocytic
leukemia, other lymphocytic leukemia, acute myeloid leukemia,
acute monocytic leukemia, chronic myeloid leukemia, and others.
We did not combine the different subtypes as they display
divergent biological and clinical characteristics [10] and display
different incidence trends over time. Using the SEERStat
program, we analyzed three groups: male patients, female patients,
and a combined database including patients of both genders. The
combined database is not independent from the other two but
contains the largest collection of cancer types, and thus is useful for
further analysis.
In addition, we obtained data on 36 cancer types from the
NORDCAN website [11], which contain information about
incidence, mortality and 5-year survival rates for the Nordic
countries: Denmark, Finland, Norway and Sweden. We excluded
data from Icelandic patients because of the small population size of
this country, which causes too much noise for valid analysis The
Nordic datasets are superior in comparison to the SEER USA
datasets, as the latter do not provide comprehensive coverage of all
US states.
We then calculated the change in incidence rates and change in
5-year survival between two chosen time points (referred to as the
initial and the final time points). In order to reduce the amount of
variation in the data, we calculated the average incidence and 5-
year survival rates over the course of several years (see SI). For the
Nordic countries, we used data averaged over the period of 1964–
1967 as the initial time point, and data averaged over the period of
2000–2003 as the final time point. For data from US patients, we
used 1973–1976 and 2000–2003 as the initial and the final time
periods.
Since patients diagnosed with cancer in a given year die a few
years later on average, the incidence and survival rates of a given
year are associated with the mortality rate of a later year. We thus
determined the association between the incidence rate in year x
and the mortality rate in year x+a. We performed sensitivity
analyses by choosing a wide range of a between 0 and 6 years and
obtained consistent results. Here, we present the results for a =3:
we calculated the changes in mortality rates during 1967–1970
and 2003–2006 for the Nordic countries, and during 1976–1979
and 2003–2006 for the US. Note that the relationship between the
year of diagnosis and the mortality year should take into account
the distribution of the death time. However, this would necessitate
the use of more information that unfortunately is usually not
available. Therefore, we used one gap time (which can be the
mean, median or mode) as a rough approximation for the whole
distribution.
Measures
We calculated the change in the incidence, mortality, 5-year
survival rates, and mortality over incidence (MOI) between the
chosen two time points in each dataset. We then measured the
correlation between the change in the 5-year survival rate and the
change in incidence and mortality rates as was done by Welch et
al. [7]. For each cancer type, the authors [7] calculated the change
in mortality, incidence and 5-year survival rates and produced a
figure showing the change in mortality versus the change in
survival; each point represented a specific cancer type. They then
calculated the correlation between the change in mortality and
change in 5-year survival, and performed a similar calculation for
the change in 5-year survival and the change in incidence. The
mortality and incidence rates have different magnitudes for
different types of cancers; therefore, in order to be able to
compare frequent and rare cancer types, they measured the
change in the rates over a certain time period as a percentage of
the initial value, rather than as an absolute value. This percentage
Is 5 Year Survival a Robust Measure?
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rates over the same time period. In addition, we calculated the
change in MOI over the two chosen time points, which was then
given as an absolute value (i.e. the mortality at the final time
divided by the incidence at the final time, minus the mortality at
the initial time divided by the incidence at the initial time) since
the MOI itself is a fraction.
Analysis
For each dataset, we investigated the correlation between
changes in survival and the other three measures, as outlined
above, using Pearson’s and Spearman’s correlations, and linear
regression. In addition, we analyzed the correlation between the
change in the incidence and the change in the mortality using the
same approaches.
Results
Using the datasets and analytic approaches outlined in
Methods, we first investigated the correlation between changes
in 5-year survival rates and incidence and mortality rates, as was
done by Welch et al. [7]. The results for all datasets are
summarized in Table 1. Figure 1 displays the results for the US
dataset as one particular example; all other plots are shown in
Figures S1–S11. The correlation between the changes in 5-year
survival rates and the changes in incidence and mortality rates are
shown in Figure 1a and b. Similar to the findings by Welch et al
[7], we also observed that there is no significant negative
correlation between the change in survival and the change in
mortality in all datasets. Meanwhile, in some datasets (see
Table 1), there is a positive correlation between the change in
survival and the change in incidence. These results were
interpreted by Welch et al. [7] to indicate that improvements in
survival rates are predominantly artificial, since a real improve-
ment in the clinical management of cancer should simultaneously
reduce mortality and enhance survival, while an artificial
improvement, due to early diagnosis, increases survival rates and
incidence rates without reducing the mortality. However, as shown
in Figure 1c, there is a strong correlation between the change in
incidence and the change in mortality. This finding indicates that
much of the change in mortality is a result of the change in
incidence, and therefore the correlation between the change in
5-year survival and the change in mortality due to improved
treatment is obscured. In Figure 1d, we present the correlation
between the change in 5-year survival rates and the change in MOI
(Pearson’s correlation coefficient 20.55, p-value =0.000075). In
the SI, we show the correlation coefficients and p-values for
alternative values of a. The correlation changes only slightly for
these alternative intervals, and is significant for all the intervals
investigated. The other datasets also display negative significant
correlations, as is shown in the SI. The size of the correlation in
some datasets is moderate (,0.5), while it is strong in others. This
difference may be due to different strengths of the artificial
improvements in 5-year survival, but also may be due to the
difference in data collection. Generally, the US datasets have
weaker correlations than those from the Nordic countries, which
may be due to the fact that with the US datasets, we divided cancer
types into more detailed subtypes, which likely adds variation to the
Figure 1. Correlations between different measures for the US dataset. (a) Change in 5-year survival versus change in mortality. (b) Change in
5-year survival versus change in incidence. (c) Change in mortality versus change in incidence. (d) Change in the 5-year survival versus change in
mortality over incidence (MOI). The Pearson’s correlation coefficient (R) and its p-value are displayed on top of each panel. The change in 5-year
survival is strongly linearly associated with the change in MOI.
doi:10.1371/journal.pone.0083100.g001
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correlation coefficient for different intervals that is shared by the
different datasets that we used. See SI for a rigorous development of
the negative correlation between the change in 5-year survival and
MOI. We also repeated our analyses using Spearman’s correlation
(see SI), and found that the changes when using this metric were
minor.
Note that we have observed the pattern expected under real
improvements in the clinical management of cancer; thus, there is
no reason to assume that improvements in cancer treatment are
not real, as implied by Welch et al. [7]. However, this observation
in itself is not proof that the improvements in cancer treatment are
real, because over-diagnosis [12] — the identification of cancer
cases due to improved diagnostic tools that would not have
resulted in death even without the diagnosis — can artificially
create a negative correlation between the change in 5-year survival
and the change in MOI. This fact arises because over-diagnosis
artificially increases both survival and incidence, resulting in a
negative correlation between the rates of survival and MOI even
without any underlying improvements in the clinical management
of cancer patients. It has recently become apparent that over-
diagnosis is a problem when investigating incidence and preva-
lence rates of some cancer types [13]. In order to tackle the
problem of over-diagnosis, we repeated our analyses of the
correlation between the change in survival and the change in MOI
using only those cancer types whose incidence did not increase
during the chosen time period. We hypothesized that for those
cancer types with stable or decreasing incidence rates, the
contribution of over-diagnosis should be very low. For the US
cohort, this approach led to the use of 35 cancer types.
When performing these analyses, we obtained a significant
negative slope between changes in survival and MOI for the US
male and combined datasets. For the US female dataset, we
obtained a negative slope for all cases, but the slope was significant
only when using mortality data from a time period of at least three
years after the date at which the incidence was determined. These
results are presented in the SI. These findings demonstrate that
also for cancer types with almost no over-diagnosis, the negative
correlation between changes in 5-year survival and in MOI still
exist; thus, it is likely that the improvements in the 5-year survival
rates are real even in cancer types where incidence rates did
increase, as there is no reason to posit a meaningfully higher over-
diagnosis rate in those cases.
The results for the US cohort are a typical example, and the
figures for all other cohorts are presented in the SI. Table 1
displays the correlation coefficients and their p-values of the
following comparisons for all available datasets: changes in 5-year
survival rates and incidence, changes in 5-year survival rates and
mortality, changes in mortality and incidence, and changes in 5-
year survival rates and MOI. Note that in all cases, there is a
negative correlation between the rates of survival and MOI, which
is always statistically significant. Also, by using only cancer types
whose incidence did not increase in the Nordic countries, we
consistently obtained a significantly negative slope for all datasets,
except for the female population in Norway for which there were
only 6 cancer types, a sample set potentially too small to allow for
significant results. Note that the mortality and incidence rates are
age-adjusted, and the adjustments of the US and the Nordic data
were potentially done differently; this might thus represent the
source for some of the differences we observed between the US
and Nordic countries.
For the US population, we repeated all calculations using 10-
year survival data instead of 5-year survival data and obtained
consistent results. The correlation between the change in 10-year
survival and the change in MOI was negative and significant for
all patients as well as for both genders. Also, when we used only
the cancer types for which the incidence did not increase, we
obtained a significantly negative correlation (see SI).
Discussion
In this paper, we have proposed an alternative approach to
investigate the effectiveness of clinical interventions against cancer
using information of incidence, survival, and mortality of cancer
patients. We showed that by comparing survival to MOI (mortality
normalized by incidence), the expected correlation patterns
between the changes in 5-year survival and MOI are obtained.
By doing so, we negated the previous claim by Welch et al. [7] that
the expected correlation cannot be observed and therefore, that 5-
year survival rates cannot be used to evaluate progress in the fight
against cancer. In addition, we demonstrated that early diagnosis
is not a major problem for the analysis of changes in survival rates.
However, this finding by itself does not prove that the effects of
artificial improvements in the 5-year survival are negligible; rather,
it shows that there is no reason to assume that their effect is large,
because even though MOI cannot improve artificially due to lead
time bias, it can still artificially improve due to over-diagnosis.
To tackle the problem of over-diagnosis, we analyzed only those
cancer types whose incidence did not increase during the time
period of observation; thus there is no reason to believe that these
cancer types are significantly influenced by over-diagnosis. For
these cancer types, we also obtained a significantly negative
correlation between the change in 5-year survival and the change
in MOI. Therefore, for these cancer types, the improvement in 5-
year survival rates is not due to early diagnosis or over-diagnosis.
The fact that we obtained the same results for cancer types with an
incidence that did not increase indicates that over-diagnosis does
not play a major role in artificially enhancing the 5-year survival
for any cancer type.
We found that in general, the changes in 5-year survival rates
contain information that can be harvested to measure our progress
in the war against cancer. While early diagnoses artificially
increase the rates of 5-year survival, in general, their effect is minor
relative to the effect of improvements in cancer treatments. This
finding becomes apparent when the survival rates are compared to
the mortality rates normalized by the incidence (MOI).
The survival measure and the MOI measure should ideally be
used in tandem to assess improvements in cancer treatments, as no
measure is perfect. Survival alone may include minor effects of
lead-time bias. The MOI measure alone does not properly capture
improved survival times in cases when mortality rates do not
change. However, improvements in the survival measure alone
can be used to provide a reliable indication of progress.
Note that the correlation between MOI and 5-year survival was
already observed by Vostakolaei et al. [14] who showed that MOI
was generally a good proxy for 5-year survival. However, our work
differs from their investigation in that we have analyzed the
correlation between the change in MOI and the change in 5-year
survival, in order to determine whether improvements in survival
rates are real. This question was not answered previously since the
authors did not compare changes in those measurements over
time, but rather looked at a single snapshot in time.
It is worth noting that other approaches to assessing the
improvements in cancer treatment can be taken, such as analyzing
the changes in the number and ratio of patients diagnosed at
different stages of cancer development. However, such methods
require more detailed information about the diagnostic tools used,
Is 5 Year Survival a Robust Measure?
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differing from the wide-scale approach we applied here.
Supporting Information
Figure S1 The correlation between the different mea-
sures for the female cohort from Denmark. (a) Change in
mortality vs change in incidence. (b) Change in 5-year survival vs
change in incidence. (c) Change in 5-year survival vs change in
mortality. (d) Change in 5-year survival vs change in mortality
over incidence (MOI). Pearson’s correlation coefficient and its p-
value are displayed on top of each panel. The change in 5-year
survival is strongly linearly associated with the change in MOI. (e–
h) Same as in (a–d), but including only those cancer types whose
incidence decreased during the time of observation.
(BMP)
Figure S2 The correlation between the different mea-
sures for the male cohort from Denmark. (a) Change in
mortality vs change in incidence. (b) Change in 5-year survival vs
change in incidence. (c) Change in 5-year survival vs change in
mortality. (d) Change in 5-year survival vs change in mortality
over incidence (MOI). Pearson’s correlation coefficient and its p-
value are displayed on top of each panel. The change in 5-year
survival is strongly linearly associated with the change in MOI. (e–
h) Same as in (a–d), but including only those cancer types whose
incidence decreased during the time of observation.
(BMP)
Figure S3 The correlation between the different mea-
sures for the female cohort from Finland. (a) Change in
mortality vs change in incidence. (b) Change in 5-year survival vs
change in incidence. (c) Change in 5-year survival vs change in
mortality. (d) Change in 5-year survival vs change in mortality
over incidence (MOI). Pearson’s correlation coefficient and its p-
value are displayed on top of each panel. The change in 5-year
survival is strongly linearly associated with the change in MOI. (e–
h) Same as in (a–d), but including only those cancer types whose
incidence decreased during the time of observation.
(BMP)
Figure S4 The correlation between the different mea-
sures for the male cohort from Finland. (a) Change in
mortality vs change in incidence. (b) Change in 5-year survival vs
change in incidence. (c) Change in 5-year survival vs change in
mortality. (d) Change in 5-year survival vs change in mortality
over incidence (MOI). Pearson’s correlation coefficient and its p-
value are displayed on top of each panel. The change in 5-year
survival is strongly linearly associated with the change in MOI. (e–
h) Same as in (a–d), but including only those cancer types whose
incidence decreased during the time of observation.
(BMP)
Figure S5 The correlation between the different mea-
sures for the female cohort from Norway. (a) Change in
mortality vs change in incidence. (b) Change in 5-year survival vs
change in incidence. (c) Change in 5-year survival vs change in
mortality. (d) Change in 5-year survival vs change in mortality
over incidence (MOI). Pearson’s correlation coefficient and its p-
value are displayed on top of each panel. The change in 5-year
survival is strongly linearly associated with the change in MOI. (e–
h) Same as in (a–d), but including only those cancer types whose
incidence decreased during the time of observation.
(BMP)
Figure S6 The correlation between the different mea-
sures for the male cohort from Norway. (a) Change in
mortality vs change in incidence. (b) Change in 5-year survival vs
change in incidence. (c) Change in 5-year survival vs change in
mortality. (d) Change in 5-year survival vs change in mortality
over incidence (MOI). Pearson’s correlation coefficient and its p-
value are displayed on top of each panel. The change in 5-year
survival is strongly linearly associated with the change in MOI. (e–
h) Same as in (a–d), but including only those cancer types whose
incidence decreased during the time of observation.
(BMP)
Figure S7 The correlation between the different mea-
sures for the female cohort from Sweden. (a) Change in
mortality vs change in incidence. (b) Change in 5-year survival vs
change in incidence. (c) Change in 5-year survival vs change in
mortality. (d) Change in 5-year survival vs change in mortality
over incidence (MOI). Pearson’s correlation coefficient and its p-
value are displayed on top of each panel. The change in 5-year
survival is strongly linearly associated with the change in MOI. (e–
h) Same as in (a–d), but including only those cancer types whose
incidence decreased during the time of observation.
(BMP)
Figure S8 The correlation between the different mea-
sures for the male cohort from Sweden. (a) Change in
mortality vs change in incidence. (b) Change in 5-year survival vs
change in incidence. (c) Change in 5-year survival vs change in
mortality. (d) Change in 5-year survival vs change in mortality
over incidence (MOI). Pearson’s correlation coefficient and its p-
value are displayed on top of each panel. The change in 5-year
survival is strongly linearly associated with the change in MOI. (e–
h) Same as in (a–d), but including only those cancer types whose
incidence decreased during the time of observation.
(BMP)
Figure S9 The correlation between the different mea-
sures for both genders from the US. (a) Change in mortality
vs change in incidence. (b) Change in 5-year survival vs change in
incidence. (c) Change in 5-year survival vs change in mortality. (d)
Change in 5-year survival vs change in mortality over incidence
(MOI). Pearson’s correlation coefficient and its p-value are
displayed on top of each panel. The change in 5-year survival is
strongly linearly associated with the change in MOI. (e–h) Same as
in (a–d), but including only those cancer types whose incidence
decreased during the time of observation.
(BMP)
Figure S10 The correlation between the different mea-
sures for the male US cohort. (a) Change in mortality vs
change in incidence. (b) Change in 5-year survival vs change in
incidence. (c) Change in 5-year survival vs change in mortality. (d)
Change in 5-year survival vs change in mortality over incidence
(MOI). Pearson’s correlation coefficient and its p-value are
displayed on top of each panel. The change in 5-year survival is
strongly linearly associated with the change in MOI. (e–h) Same as
in (a–d), but including only those cancer types whose incidence
decreased during the time of observation.
(BMP)
Figure S11 The correlation between the different mea-
sures for the female US cohort. (a) Change in mortality vs
change in incidence. (b) Change in 5-year survival vs change in
incidence. (c) Change in 5-year survival vs change in mortality. (d)
Change in 5-year survival vs change in mortality over incidence
(MOI). Pearson’s correlation coefficient and its p-value are
displayed on top of each panel. The change in 5-year survival is
strongly linearly associated with the change in MOI. (e–h) Same as
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decreased during the time of observation.
(BMP)
Table S1 USA incidence and mortality rates.
(XLSX)
Table S2 USA survival rates.
(XLSX)
Table S3 European Nordic countries incidence.
(XLS)
Table S4 European Nordic countries mortality.
(XLSX)
Table S5 European Nordic countries survival rates.
(XLSX)
Table S6 Results. Both Pearson and spearman coeffi-
cients for all the estimated correlations is given. This
information was used to generate figure 1 and S1-S11.
(XLSX)
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